



Annual Report | Fiscal Year 2017

April 1, 2016 – March 31, 2017

Inside Komen: April 1, 2016 – March 31, 2017

Letter from Connie O’Neil	2
Bold Goal Overview	4
Why Komen	9
More Than Pink	11
Generating Revenue	16
Financials Leadership	20

MAKING AN **IMPACT**

We refuse to give up. **Ever.**

Susan G. Komen works every day for the moment we can say, “No one will die of breast cancer.”

Ending breast cancer was our founder’s promise to her sister.

Today, it is our Promise to all women and men.



Every day in America, about 113 women and men die of breast cancer.

Every day in America, about 113 women and men die of breast cancer. This is one person every 13 minutes—a number that has stayed stubbornly constant despite decades of progress against the most common cancer diagnosed in women. A disappointing number as well, given the leaps and bounds made against breast cancer in the 35 years since Susan G. Komen opened its doors and launched the breast cancer movement in 1982.

It is important to speak of the progress we've made against this deadly disease; to show and celebrate the stories of women and men who have overcome breast cancer.

But what, we ask ourselves, of the more than 40,000 women and men who are still dying of breast cancer each year? Women and men who may have “beaten” breast cancer years earlier, only to find it has returned with a viciousness and cunning that turned their years-ago victory into a suddenly cruel race against time?



And what of the women and men whose odds of surviving breast cancer are significantly diminished because of the color of their skin, their economic status, their insurance provider, or even their zip code? How could we ensure that all women and men have the same fighting chance at life as their neighbors?

This was the impetus behind **More Than Pink®** – the initiative we launched in the fall of 2016 to dig below the surface of our signature color. We knew that “pink” has made many things possible. In our 35th year, we also knew we must stretch further, go deeper and set an aggressive but achievable goal that will save lives. We determined we needed to be **More Than Pink**, and set a **Bold Goal** to reduce the current number of breast cancer deaths in the U.S. by 50 percent, by 2026.

We are doing so by taking aim against the breast cancers that kill – aggressive breast cancers and metastatic breast cancer, or cancer that has spread to distant organs, where it is not curable. We also are doing so by building on our decades-long commitment to provide access to timely, high-quality care to reach women and men where they live, and by launching the African-American Health Equity Initiative, with funding from the Fund II Foundation. This is a national initiative with a local focus, targeting African-American women in the 10 cities with the greatest breast cancer disparities. Nationally, African-American women die of breast cancer at rates 40 percent higher than white women; in the 10 cities we have targeted, that rate is as much as 70 percent higher.

You will read more about these important initiatives in the pages that follow.

We determined we needed to be **More Than Pink**, and set a **Bold Goal** to reduce the current number of breast cancer deaths in the U.S. by 50 percent, by 2026.

Our research portfolio – at \$956 million since our founding – is the largest breast cancer research portfolio of any nonprofit and second only to the U.S. government. This past year’s research investment demonstrated our commitment to our Bold Goal, with more than 40 percent of our funding dedicated to research to treat, detect and one day prevent metastatic disease.

At the same time, our network of Affiliates took action to bring the metastatic community to the forefront of our work, with many launching metastatic breast cancer symposia to advocate and support women and men facing metastatic disease.

In the coming year, we will build on those national initiatives that underlie our passion for innovation, in areas like Big Data. We also will explore new ways to deliver our mission in our community, through an enhanced focus on things like patient navigation programs, which have been proven to reduce breast cancer mortality. We will build on our existing reach and seek new partnerships among breast cancer organizations and the larger nonprofit sector as well. In this way, we will extend Komen’s influence, expertise – and impact.

The Komen Board of Directors is fully committed to these initiatives, which build on Komen’s legacy of leadership and innovation – a legacy that has made a difference in the lives of millions.

As we do so, we will continue to enhance our fundraising programs and expand the potential of our signature events such as the Susan G. Komen Race for the Cure and the Komen 3-Day. There are many breast cancer and nonprofit organizations vying for donor dollars, and thousands of events in which people can participate. By better showcasing the urgency of our cause and Komen’s work to improve people’s lives, we are confident that we can motivate the one million people who currently participate in our events to deepen their relationship with us, and inspire the millions of others who are looking for a new charity of choice to make an impact through us.

We must do so, mindful always of the millions of people who count on us each year to lead in breast cancer research and community outreach – efforts that will continue to save the lives of women and men living today, and generations to follow.

Our Bold Goal sets the stage. We are marching aggressively to achieve it. The following pages show how.

Please join us.

Very truly yours,



Connie O'Neill
Chair
Susan G. Komen Board of Directors

Bold Goal Overview

Some Komen-funded researchers have lost their mothers, sisters and friends to this disease, or are living with breast cancer themselves.

Dr. Danny Welch lost six aunts to cancer. Dr. Maria Soledad Sosa's mother has breast cancer. Dr. Elizabeth Welberg's mom does, too. Other Komen-funded researchers have lost their mothers, sisters and friends to this disease, or are living with breast cancer themselves. Our eight Scientific Advisory Board (SAB) members, 70 Komen Scholars, and hundreds of research grantees and hundreds of patient advocates work every day to save people they may or may not know, to honor people they've lost, and to make a difference in the world.

These are the people behind the rather generic term "breast cancer research." We know our Komen-funded researchers to be the best and brightest in the world. They include our SAB and Komen Scholars - the pre-eminent experts of their fields - who guide our breast cancer research investment that as of FY17 was \$956 million, the largest of any nonprofit and second only to the U.S. government. We also support early-career investigators, the next generation of researchers who are bringing their creativity and energy to answer critical questions in breast cancer research. Patient advocates, too, are important members of Komen-funded research teams, providing the patient voice to help ensure the research has the greatest patient impact.

All of them are passionate about their work and helping us to achieve our **Bold Goal** to reduce the current number of breast cancer deaths in the U.S. by 50 percent by 2026. Because they are often caring for patients, they know where the cutting-edge research lies that may save lives. Because they are caring for patients, they know how lack of access to medical care determines whether some women will live or die. Because they are in the trenches - working in their communities, advocating for women and men with breast cancer, and in many cases personally impacted by breast cancer - they know all too well that our mission is urgent.



\$956M
Invested

The largest nonprofit funder of breast cancer research outside the federal government
(cumulative, since 1982)

This is why our **Bold Goal** focuses in two areas:

- On discovering and delivering breakthroughs to address metastatic breast cancer, that is, cancer that has spread to the lungs, brain, liver or bones, where it is not curable.
- On achieving health equity - ensuring access to and receipt of timely, high-quality cancer care for all.

In FY17, we increased our investment in metastatic breast cancer research to more than **40 percent** of our \$30.7 million in research funding.

In the laboratory, Komen's research funding helps Dr. Sosa find a way to put metastatic cells to sleep, before they spread. Dr. Welberg is studying how weight gain may impact breast cancer progression and response to therapy. Dr. Welch is seeking to understand why breast cancer cells metastasize in the first place – in hopes of one day of stopping metastatic breast cancer (MBC) before it develops.

And these are just three of the 96 researchers we funded this year – all working on ways to discover and deliver the cures for breast cancer, especially the breast cancers that still kill.

In FY17, we increased our investment in metastatic breast cancer research to more than 40 percent of our \$30.7 million in research funding. We supported tools such as a new metastatic trials finder (with breastcancertrials.org) to help women and men find clinical trials that can extend their lives, or contribute to a growing body of knowledge that may save others.

40+
Research Projects

Focused on finding approaches to reducing breast cancer disparities

88
New Biomarkers

Are being discovered and/or tested to help diagnose people and tailor treatment strategies to each individual

100+
Research Labs

Studying metastatic breast cancer to understand why it occurs and how to treat it

150+
New Treatments

Are being discovered and tested for breast cancer – 69 of these for triple negative breast cancer, which needs better treatment options

290
Research Teams

Working to end breast cancer – located in 32 states, Washington D.C. and 11 countries

And in our communities, Komen Affiliates brought together experts with MBC patients to address their issues and offer support and help.

Advances in medical science are already helping many women and men with MBC live longer, with a higher quality of life. That's progress, but not enough. Our goal is to first reduce death from MBC, and then to ensure that no one dies of MBC, ever again.

70

Top-level Scientists & Advocates Helping guide and prioritize Komen's global research investment, which totals \$956M+ for 2,600+ grants

190+

Emerging Scientists The next generation of leaders in breast cancer research – supported through Komen's training and career catalyst grants

200+

Komen Advocates in Science Ensuring the patient perspective is included at every step, bringing a sense of urgency and impact to Komen's research programs

In some cities, the mortality gap between African-American and Caucasian women is as high as 70 percent.

Quality Care For All

Research is critical to ending breast cancer and essential to achieving our **Bold Goal**. But ensuring quality care for all is equally important, because we have learned over our 35 years that all the research in the world will not help if its benefits don't reach women and men who need it.

Our expert advisors believe as many as 30 percent of breast cancer deaths could be avoided if all women and men had access to, and received, timely high-quality health care and used the drugs and technologies throughout the continuum of care that are available to us today.

Komen has invested more than \$2 billion in funding for local and national programs that strive to ensure women and men who need financial, medical or psychosocial support receive the help they need. Today, too many people die because of issues unrelated to actual treatment – for a lack of affordable insurance, or resources, or the support they need before, during and after their treatment.

Our Komen Affiliates are key to understanding the needs of their communities. Community partners funded by Komen provide breast cancer screenings, diagnostic tests, medical supplies, out-of-pocket medical costs, surgeries and other therapies, transportation to treatment, culturally sensitive education, patient navigation programs – even emergency living expenses.

We have led and continue to lead with programs to ensure all women and men – regardless of who they are or where they live – are served.

Health Disparities

Differences in breast cancer outcomes among specific groups, such as race/ethnicity, age, disability, socioeconomic status, sexual orientation and education

- **Late-Stage Diagnosis**
- **Barriers to Screening**
- **Fragmented Treatment**
- **High Death Rates**

Health Equity

Attainment of the highest level of breast health for all people, ensuring that everyone has full access to breast health opportunities that enable them to lead healthy lives

- **Early Stage Diagnosis**
- **Access to Screenings**
- **Coordinated Treatment**
- **Lives Saved**



African-American Health Equity Initiative

Achieving health equity requires an intense focus on areas of greatest need. The need for health equity is most critical for African-American women in the U.S., who are more than 40 percent more likely to die of breast cancer than white women.

In some cities, the mortality gap between African-American and white women is as high as 70 percent.

This must change, and Komen is partnering with the community to lead the way.

We know that locally-led programs work. In Chicago, with \$2.6 million in funding from Komen, the Metropolitan Chicago Breast Cancer Task Force was able to reduce the mortality gap between African-American and Caucasian women by 35 percent in five years – proof that a collaborative, systems-oriented approach, and a determined community, can and will save lives.

In partnership with the Fund II Foundation, Komen launched the African-American Health Equity Initiative (AAHEI) to reduce disparities in breast cancer outcomes in the African-American community. The AAHEI's initial focus is in the 10 metropolitan areas in the U.S. where the disparities are greatest.

Ours is a collaborative effort with the civic, health, government and faith leaders who are the experts and trusted community members in these cities. In each city, Komen has been convening roundtable discussions, working side-by-side with these leaders to identify the interventions they know to be the most relevant to their communities. Over time, we will take what we learn in the 10 cities to more cities and towns across the U.S.

WHY **KOMEN**

Our **Bold Goal** sets our organization's course; our focus on health equity and research, the strategies that will make our goal a reality.

This goal is a new chapter in a long story of Komen taking bold steps forward, and leading the way in the fight against breast cancer.

Komen's grassroots Network of Affiliates and supporters has been the backbone of our organization since opening our doors in 1982. Driven by passion, we tore down the stigma and shame of the words "breast cancer," launching a movement that unapologetically talked about a disease that was taking the lives of our family members and friends. Today, Komen Affiliates and volunteers nationwide work tirelessly to identify the greatest needs in each community, and then raise – and invest – funds that will meet those local needs. Whether it's transportation to and from treatment, financial support to help with the cost of care, or an experienced and caring navigator who ensures a breast cancer patient gets through the complex health care system and accesses the treatment she needs – Komen Affiliates are the hands and heart of the Mission. **Our community is an asset unlike any other – one that reaches into homes, clinics and neighborhoods across the country.**

Our organization's vision of a world without breast cancer means Komen must have a broad vision of where we've been, and where we're going. The last two decades alone have brought about significant advances in the way we detect, diagnose and treat breast cancer. **Our progress is exponential, and to stay ahead – to be smarter than breast cancer – we must learn from the past and realize the potential of the future.**

Big Data is one way Komen is again leading the way, convening experts to discuss how we safely and securely share data from patients, clinical trials, research, studies – everything – to accelerate research and bring treatments to patients faster. It is a tool that we have only just begun to wield that will allow us to discover breakthroughs for incurable cancers, address breast cancer disparities, and achieve our Bold Goal. **We have tapped powerful technology in many other facets of our lives – it's time to bring more of its benefits to breast cancer patients.**

We also look to our elected officials at the state and federal levels, holding them accountable to their constituents who are facing or may someday face breast cancer. We fight to ensure that funding is available for programs that provide the underserved with the quality care they need. We demand that policymakers sustain and increase biomedical research funding to advance scientific discovery and grow our arsenal to fight breast cancer. **We show them the need, and call on them to prioritize the health of all people – an issue that knows no party lines.**

We look around the globe, where countries face an existing or emerging breast cancer crisis, and see how we can apply our knowledge – by using the painstaking lessons we had to learn as a scientific, academic and civic community about how to care for those with breast cancer – to help countries meet the needs of their citizens, and improve the way we care for patients in our own backyard. **And ensure that where a woman lives does not determine whether she lives.**

MORE THAN **PINK**

...the stories and faces of a select few of Komen's "heroes"...


"The List" Launches More Than Pink

Our launch of **More Than Pink** celebrated "The List" – a group of everyday heroes, scientists, clinicians, advocates, community leaders, athletes, musicians, and public figures who were honored for their contributions and impact in working for women and men facing breast cancer.

"The List" honored a wide array of figures including: Dr. Mary-Claire King (discoverer of the genetic link for increased breast cancer risk); Dr. Craig Jordan (the "Father of Tamoxifen"); former First Ladies Laura Bush and Betty Ford; Princess Dina Mired of Jordan; and celebrities and public figures who have advanced our cause: WWE Superstar John Cena; singer/songwriter Jason Aldean; professional boxing champion Oscar De La Hoya; and everyday heroes such as Allison Titus and Jordan Phillips, young women whose families have been affected by breast cancer and who have raised funds to ensure that no family is affected as they were.



Dr. Mary-Claire King



Dr. Craig Jordan



Laura Bush




Lorraine Hutchinson

"The List" honorees were visible throughout National Breast Cancer Awareness Month (NBCAM), spreading the **More Than Pink** message during national sporting events, concerts, races, educational webinars, news and talk shows, social media, and beyond. Additionally, the stories and faces of a select few of Komen's "heroes" were showcased in public service announcements (PSA) and advertisements streamed on a variety of traditional and digital media platforms throughout the country.

make a bigger, bolder impact and
be “More Than Pink.”



Princess Dina Mired



Richard Roundtree



Oscar De La Hoya



Jordan Phillips

Komen announced its **Bold Goal** to reduce the current number of breast cancer deaths in the U.S. by 50 percent by 2026 and is now rallying supporters to take the extra step – make a bigger, bolder impact and be “**More Than Pink®**.” The **More Than Pink** movement kicked off in October 2016, and celebrates heroes who have made a significant impact in the fight to end breast cancer. Whether you’re the doctor who won’t give up on a patient, the volunteer who gives their free time to ensure the Race for the Cure goes off without a hitch, or the child who sells lemonade in honor of his or her mother; **More Than Pink** provides the inspiration for everyone to act, donate, and get involved.

We have committed to reduce the current number
of breast cancer deaths in the U.S. by

50% by the year 2026.

Our valued More Than **Pink** launch partners truly made More Than **Pink** possible.

Making More Than Pink Possible

Our valued More Than Pink launch partners truly made More Than Pink possible.

- **WWE** embodied the spirit of More Than Pink by becoming one of our launch partners and integrating Komen into nearly every facet of its brand. In addition to their More Than Pink merchandise sales, WWE Superstar Charlotte conducted a satellite media tour where she helped to spread the word about More Than Pink during 12 local market interviews, reaching 1.8 million viewers across the country. In addition to inviting More Than Pink to take over their WWE homepage, they honored survivors during their Monday Night Raw and WWE Smackdown Live broadcast events.
- Our longest-standing partner, **American Airlines**, featured Komen's PSAs during their in-flight broadcast and featured our hero ads in American Way Magazine. AA also experienced unprecedented fundraising success through their Miles for the Cure program, raising more than \$1 million in just 31 days.



In March 2015, Sandra Lee was diagnosed with early-stage breast cancer and publicly documented her story, leading up to her decision to undergo a double mastectomy just weeks after her diagnosis. Ms. Lee has been honored on Capitol Hill with the Congressional Families "Excellence in Cancer Awareness Award," Eleanor Roosevelt Foundation's "Val-Kill Medal of Honor" and the "Spirit of Life Award" from City of Hope. Sandra has also received the "Presidents Volunteer Service Award" and the "Ellis Island Medal of Honor" for her outspoken Activism and Advocacy on behalf of women and children's health and well-being.



“Concert for the Cure”

Multi-Platinum country music superstar and “The List” honoree Jason Aldean at the Grand Ole Opry performed his 11th annual “Concert for the Cure” as part of the venue’s 2016 “Opry Goes Pink.” After flipping the switch on the Opry’s signature barn backdrop to turn it pink, Komen representatives stood onstage as Jason presented a check for more than \$450,000 benefiting Komen Central Tennessee. Jason has been a cherished partner, contributing more than \$3.3 million to Komen since the partnership began in 2005. In addition to promoting the concert twice during an appearance on ABC’s nationally televised Good Morning America, highlights from his Opry performance also appeared in outlets including: *Rolling Stone*; 92.3 WCOL; *The Nashville Tennessean*; Country Music Television News; WWGP; WSMV-TV (CBS); *Nash Country Daily*; Taste of Country; and more.

- We were thrilled to have **Simon Property Group** sign on to be another launch partner, bringing More Than Pink to life within their 180 Mills, Malls, and Premium Outlet locations across the United States. With a \$1 million guaranteed donation per year for 2016 and 2017, Simon certainly showed us all how they are More Than Pink.
- Thanks to another launch partner, **Conde Nast**, we saw multiple familiar faces representing More Than Pink, as they placed advertisements in their magazines featuring our heroes John Cena and Allison Titus. Between their print, web, and e-newsletter support, we saw more than \$1.5 million dollars of in-kind support throughout those multiple platforms, taking More Than Pink near and far.
- In their 7th year of partnership with Komen, **Bank of America** turned More Than Pink this past October with creative hero collateral visualized throughout nearly 5,000 financial centers and 18,000 ATMs across the country.

FY 2016 - 2017
**People familiar
 with Komen’s
 More Than Pink®
 messaging are...**

270%
 more likely
 to do a
3-Day Walk

232%
 more likely
 to **volunteer**

200%
 more likely
 to **purchase**

151%
 more likely
 to **donate**

Engaging our **Donors**

Race for the Cure involves more than 850,000 participants and volunteers who have helped to raise more than \$2 billion...

Partners and Fundraisers Moving Us Closer to our Bold Goal

Heron Therapeutics Matches for the Cures

Heron Therapeutics, Inc. and Susan G. Komen supporters exceeded the goal of a matching grant challenge by raising \$2.6 million for Komen's breast cancer research and community-based programs. The Heron Matching Program launched on Giving Tuesday, Nov. 29, and extended through year-end of 2016. The program – aimed at communicating the importance of supportive care in breast cancer treatment – marked the beginning of a partnership between Susan G. Komen and Heron Therapeutics, whose goal is to help ease side effects of chemotherapy in breast cancer patients.


Fighting Aggressive Disease with Milburn & Inflammatory Breast Cancer Research Foundation

In March of 2017, the Milburn Foundation, Inflammatory Breast Cancer (IBC) Research Foundation, and Susan G. Komen teamed up for a second time to advance research into IBC – an aggressive type of breast cancer that is hard to diagnose and progresses quickly. Thanks to an innovative approach that maximized donor dollars through a matching gift campaign, and a focus on such a vital breast cancer topic, the partnership raised more than half a million dollars in just one month – surpassing the original goal ten-fold. Through vision, creative thinking and action, the organizations raised much-needed funds for IBC research.

Signature Fundraising Events

Susan G. Komen Race for the Cure

With more than 140 events across the globe, Race for the Cure involves more than 850,000 participants and volunteers who have helped to raise more than \$2 billion since its inception while educating and honoring those affected by breast cancer. Up to 75 percent of funds raised stay in the local communities to fund education, screening and treatment programs while 25 percent of the net proceeds goes towards Komen's national research program.



Allison's Story: In 2003, Allison's mother, just 34 years old, died of breast cancer, leaving behind Allison, 3, and sisters Laura, 6, and Kelley, 8 months. Each year since, Allison and her family have participated in Washington D.C.'s Susan G. Komen Race for the Cure in honor of their mother. In 2016, at age 15, Allison raised \$21,428, making her the second-largest fundraiser for the D.C. Race.

Since its inception in 2003 the event has raised more than \$820 million.

Susan G. Komen 3-Day

The Komen 3-Day is a 60-mile walk over the course of three days. In 2016, more than 10,000 walkers and crew members attended seven events across the country raising money for cutting-edge research and lifesaving treatment programs. Since its inception in 2003 the event has raised more than \$820 million.



Komen DIY (Do It Yourself) Fundraising Program

Susan G. Komen's Do-It-Yourself fundraiser program allows individuals to raise money and make an impact in the fight against breast cancer in their own unique way. The program which hosted 1,250 fundraisers throughout the year - from climbing Mt. Kilimanjaro to selling lemonade - raised more than \$1.39 million for research and community programs.

Dylan Whitesel and Sanzio Angeli, who have been friends since they were teenagers, wanted to raise money to support Dylan's mother, who had been diagnosed with Stage IV metastatic breast cancer when Dylan was in the 7th grade. Out of this commitment came Rocket4theCure. On October 26, 2014, the two friends launched 3,973 rockets simultaneously, shattering the Guinness World Record. The rockets, which people could sponsor in honor or memory of a loved one, were such a successful fundraiser that Dylan and Sanzio were able to donate \$20,000 to Komen Central Virginia, for breast cancer research, treatment and awareness programs. Dylan and Sanzio are More Than Pink.



Tina McDonough was honored as a More Than Pink hero for her 3-Day team, "Valley Girls and Guys!", which has raised more than \$2.6 million for breast cancer research and community programs.

Tina's Story: Losing a dear friend to breast cancer made Tina McDonough realize that she had to do something to ensure that no one else died of the disease. In 2007, Tina began walking in the Susan G. Komen 3-Day. Her team, "Valley Girls and Guys!", continued to grow each year and today is one of the largest 3-Day teams in the country. Tina is more than a team captain. She is a true leader, rallying others in the fight against breast cancer. But walking wasn't enough for her. In Tina's hometown of Seattle, she founded her own nonprofit with the goal of providing direct patient support to women and families battling breast cancer.

Susan G. Komen's 2016 Mother's Day digital campaign #4EveryMom celebrated all mothers...

Facebook Filter Mother's Day Impact

#4EVERY MOM

Susan G. Komen's 2016 Mother's Day digital campaign #4EveryMom celebrated all mothers - moms who support us in good and bad times, moms who live in our memories and moms who are still in the fight against breast cancer. In 2016, users joined our celebration by using a custom Komen branded 'I Love Mom' profile picture filter on Facebook with #4EveryMom. The results were amazing! It was the most successful filter Facebook has ever done for any health-related cause or nonprofit organization.

- New Facebook Likes: 1.2MM
- Views to Facebook Page: 15+MM
- Profile Filter Uploads: ~25MM
- Twitter Impressions: 36MM
- Increase to Pageviews on Komen.org: 308%

12M
likes
Facebook page

15+M
views
Facebook page

~25M
uploads
Profile filter

36M
impressions
Twitter

308%
increase
Pageviews on Komen.org

Financials | Leadership

Consolidated Statement of Financial Position

Assets:	2016	2017
Cash and cash equivalents	154,493,674	129,199,058
Investments	150,955,835	172,987,203
Receivables	39,969,851	40,873,951
Prepaid expense and other assets	3,867,213	2,508,658
Property and equipment, net	2,798,585	2,340,772
Total Assets	352,085,158	347,909,642
Liabilities:	2016	2017
Accounts payable, accrued expenses, and other payables	7,806,906	7,928,800
Deferred revenue and rent	2,560,573	2,373,457
Grants payable, net	164,476,949	139,164,800
Total Liabilities	174,844,428	149,467,057
Net Assets:	2016	2017
Unrestricted - undesignated	119,868,140	118,171,612
Unrestricted - board designated	1,000,000	1,000,000
Total unrestricted	120,868,140	119,171,612
Temporarily restricted	56,047,590	78,945,973
Permanently restricted	325,000	325,000
Total Net Assets	177,240,730	198,442,585
Total Liabilities and Net Assets	352,085,158	347,909,642

Consolidated Statement of Activities

Public support and revenue:	2016	2017
Contributions	117,880,939	143,849,044
Komen Race for the Cure & Breast Cancer 3 Day	149,489,011	136,277,657
Less: Direct benefit to donors and sponsors	(25,130,890)	(22,230,751)
Net Public Support	242,239,060	257,895,950
Revenue:	2016	2017
Investment Income/(Loss)	7,521,315	(62,240)
Other Income	515,987	586,473
Total Revenue	8,037,302	524,233
Total Net Public Support and Revenue:	250,276,362	258,420,183
Expenses:	2016	2017
Program Services	216,147,708	179,629,165
Management and General	20,719,400	23,894,582
Fundraising	31,992,548	33,694,581
Total Expenses	268,859,656	237,218,328
Change in net assets	(18,583,294)	21,201,855
Net Assets, beginning of year	195,824,024	177,240,730
Net assets end of year	177,240,730	198,442,585

Mission Advisors | Fiscal Year 2016 - 2017

Komen's Mission Advisors are the best and brightest breast cancer researchers, clinicians, advocates and other experts who help guide and implement our mission programs.

Thanks to their efforts, we're driving discovery, affecting change and accelerating progress in the fight against breast cancer.

Scientific Advisory Board

The Scientific Advisory Board (SAB) provides strategic guidance and direction for our research and scientific programs, and plays a key role in guiding and prioritizing Komen's global research investment.

The SAB is led by Komen's chief scientific advisors.

George Sledge, Jr., M.D., Chief Scientific Advisor

Stanford University School of Medicine
Stanford, CA

Eric Winer, M.D., Chief Scientific Advisor

Dana-Farber Cancer Institute
Boston, MA

Carlos Arteaga, M.D.

Vanderbilt-Ingram Cancer Center
Nashville, TN

Myles Brown, M.D.

Dana-Farber Cancer Institute
Boston, MA

Powel Brown, M.D., Ph.D.

The University of Texas
MD Anderson Cancer Center
Houston, TX

Karen Gelmon, M.D., F.R.C.P.C.

British Columbia Cancer Agency
Vancouver, Canada

Cheryl Jernigan, C.P.A., F.A.C.H.E.

Advocate in Science
Komen Greater Kansas City Affiliate
Kansas City, MO

Amelie Ramirez, Dr. P.H.

The University of Texas
Health Science Center at San Antonio
San Antonio, TX



Komen Scholars

an advisory group of 62 distinguished leaders in breast cancer research and advocacy.

Representing more than 35 institutions in six countries, their expertise spans everything from clinical research, laboratory research, pathology, prevention, radiation oncology, surgery and other disciplines and specialties.

They contribute to our programs, activities and events in many ways — most notably by leading and participating as reviewers in our scientific grants review process — and act as our ambassadors in communities around the U.S. and the world.

Several of the Komen Scholars are Advocates in Science who ensure that the unique perspectives of those affected by breast cancer are fully integrated into decisions at every step of the research process.

Benjamin Anderson, M.D.

Fred Hutchinson Cancer Research Center – University of Washington School of Medicine
Seattle, WA

Alan Ashworth Ph.D., F.R.S.

UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Sunil Badve, M.D., F.R.C.Path.

Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, IN

Kimberly Blackwell, M.D.

Duke University School of Medicine
Durham, NC

Melissa L. Bondy, Ph.D.

Baylor College of Medicine,
Houston Tx

Abenaa M. Brewster, MD, MHS

The University of Texas M.D. Anderson Cancer Center,
Houston, TX

Joan Brugge, Ph.D.

Harvard Medical School
Boston, MA

Lisa A. Carey, M.D.

UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Jason S. Carroll, Ph.D.

Cancer Research UK and University of Cambridge,
Cambridge, UK

Mary L. “Nora” Disis, M.D.

University of Washington,
Seattle, WA

Susan M. Domchek, M.D.

Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

Karen Durham

Advocate in Science
Komen Tyler Affiliate
Tyler, TX

Matthew Ellis, M.B., Ph.D., B. Chir.

Baylor College of Medicine
Houston, TX

Sandra Finestone, Psy.D.

Advocate in Science
Inland Empire and Orange County Affiliates
Costa Mesa, CA

William Foulkes, M.B.BS., Ph.D.

McGill University
Montreal, Canada

Patricia Ganz, M.D.

University of California, Los Angeles
Los Angeles, CA

Judy Garber, M.D., M.P.H.

Dana-Farber Cancer Institute
Boston, MA

Sharon Giordano, M.D., M.P.H.

The University of Texas
MD Anderson Cancer Center
Houston, TX

Julie Gralow, M.D.

University of Washington School of Medicine,
Seattle, WA

Joe Gray, Ph.D.

Knight Cancer Institute – Oregon Health and Science University
Portland, Oregon

Daniel Hayes, M.D.

The University of Michigan Comprehensive Cancer Center
Ann Arbor, MI

Dawn L. Hershman, M.D., M.S.

Columbia University Medical Center,
New York, NY

Judy Johnson, M.B.A.

Advocate in Science
Komen St. Louis Affiliate
St. Louis, MO

Peggy Johnson

Advocate in Science
Komen Kansas Affiliate
Wichita, KS

Yibin Kang, Ph.D.

Princeton University,
Princeton, NJ

Mary-Claire King, Ph.D.

University of Washington School of Medicine
Seattle, WA

Tari A. King, M.D.

Dana-Farber Cancer Institute,
Boston, MA

Keith L. Knutson, Ph.D.

Mayo Clinic (Jacksonville),
Jacksonville, FL

Ian Krop, M.D., Ph.D.

Dana-Farber Cancer Institute
Boston, MA

Adrian Lee, Ph.D.

University of Pittsburgh Cancer Institute
Pittsburgh, PA



Mia A. Levy, M.D., PH.D.

Vanderbilt-Ingram Cancer Center,
Nashville, TN

Jennifer A. Ligibel, M.D.

Dana-Farber Cancer Institute,
Boston, MA

David H. Livingston, M.D.

Dana-Farber Cancer Institute
Boston, MA

David Mankoff, M.D., Ph.D.

Perelman School of Medicine - University
of Pennsylvania
Philadelphia, PA

Kathy D. Miller, M.D.

Indiana University Melvin and Bren
Simon Cancer Center
Indianapolis, IN

Gordon B. Mills, M.D., PH.D.

The University of Texas M.D. Anderson
Cancer Center,
Houston, TX

Harikrishna Nakshatri, B.V.Sc., Ph.D.

Indiana University School of Medicine,
Indianapolis, IN

Anna M. Napoles, PH.D., M.P.H.

University of California, San Francisco,
San Francisco, CA

Lisa A. Newman, M.D., M.P.H.

Henry Ford Health System,
Detroit, MI

Steffi Oesterreich, PH.D.

University of Pittsburgh,
Pittsburgh, PA

Ann Partridge, M.D., M.P.H

Dana-Farber Cancer Institute
Boston, MA

Rena Pasick, Dr. P.H.

UCSF Helen Diller Family
Comprehensive Cancer Center
San Francisco, CA

Charles M. Perou, PH.D,

University of North Carolina,
Chapel Hill, NC

Lori J. Pierce, M.D., FASCO, FASTRO

University of Michigan,
Ann Arbor, MI

Jennifer A. Pietenpol, PH.D.

Vanderbilt-Ingram Cancer Center,
Nashville, TN

Kornelia Polyak, M.D., PH.D.

Dana-Farber Cancer Institute,
Boston, MA

Lajos Pusztai, M.D., D.PHIL

Yale University,
New Haven, CT

Deborah J. Rhodes, MD

Mayo Clinic (Rochester),
Rochester, MN

Jeffery M. Rosen, PH.D.

Baylor College of Medicine,
Houston, TX

Bryan P. Schneider, M.D.

Indiana University School of Medicine,
Indianapolis, IN

Patricia Spears

Advocate in Science
Komen NC Triangle to the Coast Affiliate
Raleigh, NC

Neil Spector, M.D.

Duke University School of Medicine
Durham, NC

Melinda L. Telli, M.D.

Stanford University School of Medicine,
Stanford, CA

Geoffrey M. Wahl, PH.D.

The Salk Institute,
La Jolla, CA

Danny Welch, Ph.D.

University of Kansas Cancer Center
Kansas City, KS

Alana L. Welm, PH.D.

Huntsman Cancer Institute,
Salt Lake City, UT

Julia White, M.D.

Stephanie Spelman Comprehensive
Breast Center The Ohio State University
Medical School
Columbus, OH

Antonio Wolff, M.D.

Sidney Kimmel Comprehensive Cancer
Center - Johns Hopkins University
School of Medicine
Baltimore, MD

Kimberly Wright

Advocate In Science
Komen Maryland Affiliate
Reistertown, MD

Douglas Yee, M.D.

Masonic Cancer Center - University of
Minnesota School of Medicine
Minneapolis, MN

Susan G. Komen Board of Directors | Fiscal Year 2016 -2017

Jane Abraham
Nancy Brinker, Founder
Kaye Ceille
Linda Custard
Alan Feld
Janet Frantz
Dan Glennon
Melissa Maxfield
Olufunmilayo Olopade
Connie O'Neill
Meghan Shannon
Trish Wheaton
Linda Wilkins
Angela Zepeda

Susan G. Komen Officers | Fiscal Year 2016 -2017

Judith A. Salerno, M.D., M.S., President and CEO
Ellen Willmott, General Counsel and Secretary
Bob Green, Chief Financial Officer
Christina Alford, SVP, Development
Carrie Walsh, SVP, Marketing
Victoria Wolodzko, VP, Research and Community Health Program Operations
Miguel Perez, VP, Affiliate Network
Leslie Lurie, Deputy Counsel and Assistant Secretary
Eric Montgomery, VP, Information Technology



We refuse to give up. **Ever.**

